GSK's Hal Barron buys a $250M stake in George Scangos' Vir and makes a beeline to the clinic with Covid-19 antibodies
GlaxoSmithKline is diving straight into the swirling waters of Covid-19 R&D work, and investing $250 million to grab a chunk of equity in one of the emerging stars in infectious disease research to make it official.
GSK put out word this morning that it is partnering with Vir Biotechnology $VIR, the infectious disease startup founded in the Bay Area by former Biogen CEO George Scangos. They’re planning a leap into Phase II studies for 2 preclinical antibody candidates — VIR-7831 and VIR-7832 — that have been engineered to target the SARS-CoV-2 spike protein.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,700+ biopharma pros reading Endpoints daily — and it's free.